

First to Activate & Randomize, Enrolling 212.3% of the Target Goal in a Phase 2b CSU Trial

Our Objectives

DelRicht Research was selected as a participating site network for a Phase 2b trial targeting adults with a history chronic spontaneous urticaria (CSU). The trial aimed to recruit adults aged 18 years or older.

- **Study Enrollment Goal:** 160 patients across 53 sites
- **DelRicht's Enrollment Goal:** 21.1 patients across 7 sites
- **Patient Population:** Adults ≥18 years old
- **Enrollment Period:** February 2025 – August 2025 (5.5 mos)

Activation to Screening Timeline



The Study

Client: Mid-Size Biopharma

Trial: U.S. Phase 2b CSU

Participating PIs

Dr. Christie Matter | Prosper, TX

Dr. Christopher Kling | Wildwood, MO

Dr. Deirdre Hooper | New Orleans, LA

Dr. Ira Thorla | Baton Rouge, LA

Dr. Michael Lovelace | Louisville, KY

Dr. Olabisi Badmus | Charlotte, NC

Dr. Pezhman Shoureshi | Smyrna, TN

Key Trial Challenges & Solutions

CHALLENGES

Requiring patients to complete **1) daily Urticaria Activity Score (UAS) entries** within a strict evening window created significant **patient burden** and required **2) diligent after-hours support** to maintain data integrity.



HOW DELRICHT ADDRESSED

Sites addressed by implementing **1) proactive patient education for UAS score entry requirements** and **2) dedicating coordinators paired with automated reminders** and 24/7 support for troubleshooting eDiary entries.

Our Results

DelRicht achieved **First Site Activation** and **First Patient Randomized studywide led by Dr. Deirdre Hooper**. In addition, our 7 sites averaged a **5.7 day activation to screening timeline** and **enrolled 66 participants, 212.3% of the expected enrollment goal**. These enrollment milestones highlight the strength of our operational excellence and ability to deliver consistent, high-quality data for sponsors.

 **1st** Site Activation & Patient Randomized (Dr. Hooper)

 **66** Patients Enrolled Across 7 Sites

 **212.3%** of the Expected Enrollment Goal